Polyrizon Ltd. (PLRZ) surged 53.37 percent to $1.39 on Tuesday after announcing promising preclinical results for its PL-14 Allergy Blocker, part of the company's proprietary Capture & Contain platform.
Shares opened at $1.06 and traded between $1.03 and $1.87, compared to the previous close of $0.91 on the Nasdaq. The stock's 52-week range is $0.55 to $1,200. Volume spiked to 89.48 million shares, well above the average of 4.93 million.
The study, conducted with the University of Parma, showed PL-14 achieved over 60 percent deposition in the nasal vestibule the primary site of early allergen contact supporting its potential as a barrier-forming treatment for allergic rhinitis.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.